CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
美国移植与细胞治疗学会和美国血液学会关于造血细胞移植与 CAR-T 细胞受者 2019 冠状病毒病疫苗接种的常见问题
英文原题：Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology.
查看英文原题
Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的2019冠状病毒病（COVID-19）对免疫功能低下和老年患者的影响尤为严重。造血细胞移植（HCT）和嵌合抗原受体（CAR）T细胞接受者不仅面临更高的重症COVID-19和COVID-19相关并发症风险，而且对当前可用的COVID-19疫苗可能产生次优的免疫应答。优化这些患者中COVID-19疫苗的使用、接种时机和剂次，可能提供更好的针对SARS-CoV-2感染的保护以及感染后更好的结局。为此，来自美国移植与细胞治疗学会移植感染性疾病特别兴趣小组和美国血液学会的当前HCT和CAR-T 细胞接受者COVID-19疫苗接种指南以常见问题解答的形式提供。
展开英文摘要原文
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), disproportionately affects immunocompromised and elderly patients. Not only are hematopoietic cell transplantation (HCT) and chimeric antigen receptor (CAR) T-cell recipients at greater risk for severe COVID-19 and COVID-19-related complications, but they also may experience suboptimal immune responses to currently available COVID-19 vaccines.
Optimizing the use, timing, and number of doses of the COVID-19 vaccines in these patients may provide better protection against SARS-CoV-2 infection and better outcomes after infection. To this end, current guidelines for COVID-19 vaccination in HCT and CAR T-cell recipients from the American Society of Transplantation and Cellular Therapy Transplant Infectious Disease Special Interest Group and the American Society of Hematology are provided in a frequently asked questions format.
论文信息
- 作者
- Khawaja F、Papanicolaou G、Dadwal S、Pergam SA、Wingard JR、Boghdadly ZE、Abidi MZ、Waghmare A
- 单位
- Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: fkhawaja@mdanderson.org.United States
- 文献类型
- 临床实践指南
- 期刊
- Transplantation and cellular therapy2023 Jan
- 原文标识
- PubMed 36273782 · DOI 10.1016/j.jtct.2022.10.010
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →